News for '-ranbaxy'

Ranbaxy in-licenses new asthma drug

Ranbaxy in-licenses new asthma drug

Rediff.com17 May 2006

Ranbaxy Laboratories Limited said on Wednesday it had entered into an in-licensing agreement with Netherlands-based Eurodrug Laboratories for introducing the asthma product Doxophylline in India.

Ranbaxy launches heart disease drug in India

Ranbaxy launches heart disease drug in India

Rediff.com10 Jun 2010

Ranbaxy Laboratories on Thursday launched a generic version of Prasugrel, used in treating heart diseases, from Daiichi Sankyo portfolio in India as part of strategy to launch drugs from the parent company's stable.

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Rediff.com25 Mar 2015

The merger has fortified Sun Pharma's position.

Daiichi Sankyo to launch Ranbaxy's drugs in Japan

Daiichi Sankyo to launch Ranbaxy's drugs in Japan

Rediff.com9 Nov 2009

The company is working on a synergy plan with Ranbaxy under which Daiichi Sankyo's product will be introduced in emerging markets through Ranbaxy, he said, declining to give further details.

Matrix, ONGC, Ranbaxy top wealth creators

Matrix, ONGC, Ranbaxy top wealth creators

Rediff.com8 Jan 2007

Pharmaceutical major Matrix Laboratories, public sector oil producer Oil and Natural Gas Corporation and Ranbaxy Laboratories have emerged as the fastest, biggest and the most consistent wealth creators for year 2006

It's turnaround time for Ranbaxy Labs

It's turnaround time for Ranbaxy Labs

Rediff.com22 Oct 2007

The company recorded a net profit of Rs 426.9 crore (Rs 4.26 billion) in the first nine months against Rs 366.5 crore (Rs 3.66 billion) for the same period in 2006. With another quarter to go, the company expects profits close to Rs 739.3 crore (Rs 7.39 billion).

Ranbaxy launches anti-fungal chemical in India

Ranbaxy launches anti-fungal chemical in India

Rediff.com4 Jan 2010

The company has launched a new chemical entity Lulifin (Luliconazole) in the Indian dermatology market, the pharma major said in a filing to the Bombay Stock Exchange.

Ranbaxy global sales cross $1 billion

Ranbaxy global sales cross $1 billion

Rediff.com9 Mar 2004

Leading pharmaceutical company Ranbaxy Laboratories on Tuesday said its global sales had crossed the $1 billion mark in February 2003-February 2004 on a moving annual total (MAT) basis.

40 years ago and now: How Ranbaxy moved out of family control

40 years ago and now: How Ranbaxy moved out of family control

Rediff.com22 Oct 2014

Ranbaxy did its maiden public issue in 1973.

Relief for Ranbaxy in drug price tussle

Relief for Ranbaxy in drug price tussle

Rediff.com17 May 2010

The Delhi High Court has quashed a demand of approximately Rs 5 crore (Rs 50 million) raised by the central government against Ranbaxy Laboratories.

Ranbaxy to market Cefprozil in USA

Ranbaxy to market Cefprozil in USA

Rediff.com15 Dec 2006

Ranbaxy Laboratories will soon join the select club of Indian pharmaceutical majors and have a share in the $76.6 million generics market for anti-infective Cefprozil tablets in the US.

Ranbaxy gets USFDA nod for new drug

Ranbaxy gets USFDA nod for new drug

Rediff.com1 Apr 2005

Ranbaxy Laboratories on Friday said it had received approval from US Food and Drug Administration to manufacture and market nitrofurantoin monohydrate macrocrystals capsules (100 mg) and planned to bring the new drug to the market in April.

Ranbaxy to sell 'Doktor Mom' in Romania

Ranbaxy to sell 'Doktor Mom' in Romania

Rediff.com5 Jul 2005

JB Chemicals & Pharmaceuticals has entered into an in-licensing agreement with Ranbaxy Laboratories for marketing its herbal brand 'Doktor Mom' in Romania.

Advani snubs Ranbaxy deal

Advani snubs Ranbaxy deal

Rediff.com23 Jun 2008

Profit motives shouldn't override national interests, said BJP leader at the Business Standard annual awards function. Though he did not name Ranbaxy, the signal from the Bharatiya Janata Party's prime ministerial candidate was clear.

Ranbaxy offers generic Tamiflu to US

Ranbaxy offers generic Tamiflu to US

Rediff.com2 Dec 2005

Leading Indian pharmaceutical company Ranbaxy Laboratories Limited has offered to provide oseltamivir phosphate capsules

Ranbaxy finding ways to make acquisitions work

Ranbaxy finding ways to make acquisitions work

Rediff.com16 Nov 2009

Ranbaxy, originally promoted by the Singh family, was acquired by Japan's Daiichi Sankyo late last year.

Ranbaxy to pay damages in price-fixing case

Ranbaxy to pay damages in price-fixing case

Rediff.com26 Dec 2008

Drug maker agrees to cooperate with Scottish investigation.

Ranbaxy set for $400mn FCCB

Ranbaxy set for $400mn FCCB

Rediff.com13 Feb 2006

Now, Ranbaxy buys Ethimed of Belgium

Now, Ranbaxy buys Ethimed of Belgium

Rediff.com30 Mar 2006

India's biggest drugmaker Ranbaxy on Thursday acquired the 10th largest generic company in Belgium, Ethimed NV, for an undisclosed sum, a day after it shelled out $324 million to buy Terapia in Romania.

Ranbaxy buys Terapia for $324 million

Ranbaxy buys Terapia for $324 million

Rediff.com29 Mar 2006

India's leading drug-maker Ranbaxy on Wednesday said it has acquired Terapia, the largest independent generic company in Romania, for $324 million and aims to make that country its manufacturing hub in Europe.

Watson sends patent challenge notice to Ranbaxy for acne drug

Watson sends patent challenge notice to Ranbaxy for acne drug

Rediff.com20 Sep 2013

The drug is licensed to Ranbaxy Laboratories from Cipher Pharmaceuticals Inc of Mississauga, Ontario. It is currently protected by two issued patents listed in the FDA's approved drug products list, which expire in September 2021, the company said in a statement.

Ranbaxy launches first branded product in UK

Ranbaxy launches first branded product in UK

Rediff.com5 Mar 2004

Leading pharmaceutical company Ranbaxy Laboratories on Friday announced the launch of its first branded prescription product, Visclair, in the United Kingdom.

Ranbaxy to pay heavily for future US violations

Ranbaxy to pay heavily for future US violations

Rediff.com27 Jan 2012

Ranbaxy has also agreed to relinquish any 180-day marketing exclusivity that it might have for three pending generic drug applications.

Ranbaxy's diabetes drug gets US FDA nod

Ranbaxy's diabetes drug gets US FDA nod

Rediff.com22 Jun 2004

Ranbaxy on Tuesday announced it had got final approval from the US Food and Drug Administration to market its Metformin HC1 tablets for diabetes.

AstraZeneca sues Ranbaxy over Nexium

AstraZeneca sues Ranbaxy over Nexium

Rediff.com23 Nov 2005

AstraZeneca files suit against Ranbaxy

AstraZeneca files suit against Ranbaxy

Rediff.com22 Nov 2005

Global pharma firm AstraZeneca on Tuesday said it had filed a lawsuit in the United States District Court of New Jersey

Ranbaxy to make China a major sourcing hub

Ranbaxy to make China a major sourcing hub

Rediff.com13 Oct 2007

Pharmaceuticals major Ranbaxy Laboratories plans to leverage the cost advantage of Chinese raw materials by making China its major active pharmaceutical ingredient sourcing hub.

'Ranbaxy got USFDA nod with no data or fraudulent data'

'Ranbaxy got USFDA nod with no data or fraudulent data'

Rediff.com7 Nov 2013

In May this year, Ranbaxy had pleaded guilty to 'felony charges' for violating manufacturing norms and agreed to pay $500 million penalty to US authorities.

Wal-Mart faces ire over Ranbaxy drugs

Wal-Mart faces ire over Ranbaxy drugs

Rediff.com26 Jun 2009

WakeupWalmart.com, an anti-Wal-Mart website which belongs to the United Food and Commercial Workers Union, came out with a report two days ago titled, 'Wal-Mart's vaunted $4 prescriptions supplied by disgraced Indian manufacturer.' UFCW claims to have a membership of over 1.3 million workers in the US and Canada. WakeupWalmart.com mainly campaigns for the rights of Wal-Mart employees and consumer interests.

Ranbaxy to set up subsidiary in Spain

Ranbaxy to set up subsidiary in Spain

Rediff.com6 Feb 2004

Pharmaceutical major Ranbaxy Laboratories on Friday said it will set up a wholly-owned subsidiary in Spain as part of its strategy to expand presence in Europe.

Daiichi, Ranbaxy team to counter FDA charges

Daiichi, Ranbaxy team to counter FDA charges

Rediff.com27 Feb 2009

The USFDA has accused Ranbaxy of falsifying data and test results of medicines. A Daiichi Sankyo statement said it takes the issue very seriously. 'Both Daiichi and Ranbaxy have formed a team to solve the issue. Ranbaxy will be responding to the FDA and will continue to cooperate with the agency.' Ranbaxy shares fell more than 18 per cent to Rs 169.85 today on the Bombay Stock Exchange, while Daiichi stock dropped about 10 per cent to yen 1,680 on the Tokyo Stock Exchange.

Ranbaxy gets FDA nod for drugs

Ranbaxy gets FDA nod for drugs

Rediff.com9 Sep 2004

Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market Fosinopril Sodium and Hydrochlorothiazide tablets in 10 mg/12.5 mg and 20 mg/12.5 mg strengths

Setback for Ranbaxy in Ireland on Lipitor case

Setback for Ranbaxy in Ireland on Lipitor case

Rediff.com10 Jul 2007

In its ongoing patent litigation over cholesterol lowering drug atorvastatin (Lipitor) against India's Ranbaxy Laboratories, Pfizer said on Tuesday in a court in Ireland had ruled in its favour.

Ranbaxy to buy RPG Aventis in France

Ranbaxy to buy RPG Aventis in France

Rediff.com13 Dec 2003

Ranbaxy Laboratories Ltd will acquire RPG Aventis SA along with its fully-owned subsidiary, OPIH SARL, in France for an undisclosed sum.

Ranbaxy wins US court battle against Glaxo

Ranbaxy wins US court battle against Glaxo

Rediff.com8 Apr 2004

Pharma major Ranbaxy Laboratories on Thursday said it has scored a legal victory with a United States court ruling that its Cefuroxime Exetil product does not infringe upon the patent rights of GlaxoSmithKline.

Veronica Lab, SRL Ranbaxy in pact

Veronica Lab, SRL Ranbaxy in pact

Rediff.com19 Apr 2004

Veronica Laboratories has tied up with SRL Ranbaxy Ltd, a special reference laboratory, to carry out clinical investigations in HIV positive patients.

Ind-Swift opens facility for Ranbaxy

Ind-Swift opens facility for Ranbaxy

Rediff.com13 Jun 2005

WHO drops 3 Ranbaxy AIDS drugs

WHO drops 3 Ranbaxy AIDS drugs

Rediff.com5 Aug 2004

Ranbaxy eyes more acquisitions

Ranbaxy eyes more acquisitions

Rediff.com26 May 2006